Benlysta

Systemic Lupus Erythematosus (SLE)

Benlysta is used to treat active, autoantibody-positive systemic lupus erythematosus (SLE) in adults and children aged 5 years and older. It is typically prescribed for patients who are already receiving standard lupus treatments but still have active disease symptoms.

Lupus Nephritis

This medication is also approved to treat active lupus nephritis in adults and children aged 5 years and older. Lupus nephritis is a condition where the immune system attacks the kidneys, causing inflammation and potential damage, and is a common complication of SLE.

Usage and Limitations

Benlysta is intended to be used alongside other standard lupus therapies. However, there are specific situations where its use is not recommended or has not been fully studied:

• It is not recommended for people with severe active central nervous system lupus.
• It has not been studied in combination with other biologic medications.
• It has not been studied for use with intravenous cyclophosphamide.

Mechanism of Action

Benlysta is a monoclonal antibody, which is a type of protein designed to recognize and attach to a specific substance in the body. It works by binding to a protein called B-lymphocyte stimulator (BLyS).

Targeting B-Cells

B-cells are a type of white blood cell that play a key role in the immune system. In people with systemic lupus erythematosus (SLE) or lupus nephritis, these cells can become overactive and produce autoantibodies. These autoantibodies mistakenly attack the body's own healthy tissues, leading to inflammation and organ damage.

BLyS is a protein that B-cells need to survive and mature. People with lupus often have high levels of BLyS, which allows abnormal B-cells to survive longer and continue attacking the body.

Reducing Disease Activity

When Benlysta attaches to BLyS, it prevents the protein from stimulating B-cells. By blocking this signal, the medication helps to:

• Reduce the number of abnormal B-cells in the body.
• Lower the production of autoantibodies that cause inflammation.
• Decrease the overall activity of the disease and help prevent flares.

By limiting the immune system's attack on healthy tissues, Benlysta helps manage the symptoms of lupus and may reduce the risk of long-term organ damage.

Common Side Effects

The most frequently reported side effects of Benlysta include:

• Nausea and diarrhea
• Fever
• Headache
• Cold-like symptoms, such as a stuffy nose, sore throat, or cough
• Pain in the arms or legs
• Difficulty sleeping (insomnia)
• Injection site reactions, such as pain, redness, or itching

Serious Side Effects

Some side effects can be severe. Seek medical help immediately if you experience:

• Serious Infections: Symptoms like fever, chills, painful urination, or coughing up mucus.
• Allergic Reactions: Hives, itching, swelling of the face or throat, and trouble breathing. These reactions can sometimes occur days after treatment.
• Infusion Reactions: Dizziness, nausea, or low blood pressure occurring during or shortly after an infusion.
• Mental Health Issues: New or worsening depression, anxiety, or thoughts of hurting yourself.
• Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection that may cause confusion, vision changes, or problems with balance and movement.

Infections

Benlysta works by affecting the immune system, which can make it harder to fight off infections. Some infections may be serious or life-threatening. Healthcare providers generally check for active or chronic infections before starting treatment and monitor for new symptoms during therapy.

Allergic and Infusion Reactions

Serious allergic reactions, including anaphylaxis, have occurred in patients receiving Benlysta. These reactions can happen during the infusion or may be delayed by several hours or days. Symptoms may include:

• Swelling of the face, lips, or tongue
• Difficulty breathing or wheezing
• Rash or hives
• Low blood pressure or dizziness

Mental Health Concerns

There is an increased risk of depression, suicidal thoughts, and other mood changes associated with this medication. It is important to watch for signs such as new or worsening anxiety, thoughts of self-harm, or unusual changes in behavior.

Progressive Multifocal Leukoencephalopathy (PML)

PML is a rare but very serious brain infection that has been reported with Benlysta use. This condition is caused by a virus and can lead to severe disability or death. Symptoms may include confusion, loss of coordination, or vision problems.

Vaccinations

Live vaccines should not be given within 30 days of starting Benlysta or while the medication is being used. The immune response to other vaccines may also be less effective during treatment.

Cancer Risk

The effect of Benlysta on the development of malignancies is not well established. However, medications that suppress the immune system may potentially increase the risk of developing certain types of cancer.

Pregnancy

There is limited information regarding the use of Benlysta in pregnant women. Because Benlysta is a monoclonal antibody, it can cross the placenta and may affect the developing fetus. Animal studies have not shown a clear risk of harm, but human data are insufficient to determine if there is a drug-associated risk of major birth defects or miscarriage.

Healthcare providers may encourage patients who become pregnant while taking Benlysta to enroll in a pregnancy registry. These registries collect information to help researchers understand the effects of the medication on pregnancy outcomes.

Contraception

Individuals who can become pregnant should use effective birth control during treatment with Benlysta. This should continue for at least four months after the final dose, as the medication can remain in the body for an extended period.

Breastfeeding

It is currently unknown whether Benlysta passes into human breast milk or if it has any effect on a nursing infant or milk production. While many antibodies are excreted in human milk, the amount absorbed by the infant is generally thought to be low. Patients should discuss the risks and benefits of breastfeeding while using this medication with their healthcare provider.

Available Forms

Benlysta is supplied in two primary formats depending on the method of administration:

• Intravenous (IV) Infusion: This form is a powder provided in single-dose vials. A healthcare professional must reconstitute and dilute the powder before administering it into a vein over a period of about one hour.
• Subcutaneous Injection: This form is a liquid solution available in single-dose prefilled autoinjectors or single-dose prefilled syringes. It is designed for injection under the skin of the stomach area or thigh.

FDA Approval History

Benlysta was first approved by the U.S. Food and Drug Administration (FDA) in March 2011. It was the first new drug approved for systemic lupus erythematosus (SLE) in over 50 years. The FDA later expanded its approval to include a subcutaneous injection form in 2017 and pediatric use for children aged 5 and older in 2019.

Approved Indications

The FDA has approved Benlysta for use in the following populations:

• Adults and children (5 years and older) with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
• Adults and children (5 years and older) with active lupus nephritis who are receiving standard therapy.

Benlysta is not recommended for patients with severe active central nervous system lupus or for use in combination with other biological therapies.

Safety and Monitoring

There are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for Benlysta. The FDA-approved labeling includes precautions regarding the risk of serious infections, hypersensitivity reactions, and psychiatric events such as depression or suicidal behavior. Patients are monitored for these risks as part of standard clinical practice.

Factors Influencing Cost

Several factors determine the total out-of-pocket expense for Benlysta treatment:

• Administration Method: Benlysta is available as an intravenous (IV) infusion administered by a healthcare professional or as a subcutaneous injection that can be self-administered. Costs may differ between these forms.
• Insurance Coverage: Most commercial insurance plans and Medicare provide coverage for Benlysta, though the specific copay or coinsurance amount depends on the individual plan's formulary.
• Prior Authorization: Insurance providers often require prior authorization, meaning the doctor must prove the medication is medically necessary before the plan will cover the cost.

Financial Assistance Programs

Because Benlysta is a specialty biologic medication with a high list price, financial support options are often available to help manage costs:

• Copay Program: The manufacturer offers a copay assistance program for eligible patients with commercial (private) insurance, which can significantly reduce monthly out-of-pocket costs.
• Patient Assistance: For individuals who are uninsured or underinsured, patient assistance programs may provide the medication at no cost if specific income and eligibility requirements are met.
• Government Programs: Patients with Medicare, Medicaid, or other government-funded insurance are generally not eligible for manufacturer copay cards but may qualify for other forms of low-income subsidies or independent foundation support.

Specialty Pharmacy Requirements

Benlysta is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. These pharmacies specialize in handling complex medications that require specific storage conditions, such as refrigeration, and provide additional support services for patients.